Published in AIDS Res Hum Retroviruses on February 01, 1992
Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J (1993) 4.39
Identification of the catalytic and DNA-binding region of the human immunodeficiency virus type I integrase protein. Nucleic Acids Res (1993) 3.42
Complementation between HIV integrase proteins mutated in different domains. EMBO J (1993) 3.32
Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection. J Virol (1996) 2.82
The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA binding. J Virol (1994) 2.56
Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO J (1997) 2.42
Genetic analysis of the human immunodeficiency virus type 1 integrase protein. J Virol (1994) 2.26
Characterization of the minimal DNA-binding domain of the HIV integrase protein. Nucleic Acids Res (1994) 1.98
Human immunodeficiency virus type 1 integrase: effect on viral replication of mutations at highly conserved residues. J Virol (1994) 1.84
Characterization of a DNA binding domain in the C-terminus of HIV-1 integrase by deletion mutagenesis. Nucleic Acids Res (1993) 1.79
Retroviral DNA integration. Microbiol Mol Biol Rev (1999) 1.64
Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants. J Virol (2004) 1.56
Mutations in the human immunodeficiency virus type 1 integrase D,D(35)E motif do not eliminate provirus formation. J Virol (1998) 1.44
Formation of a stable complex between the human immunodeficiency virus integrase protein and viral DNA. Nucleic Acids Res (1994) 1.40
Structural biology of retroviral DNA integration. Virology (2011) 1.37
Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase. J Virol (2005) 1.28
Comparison of DNA binding and integration half-site selection by avian myeloblastosis virus integrase. J Virol (1993) 1.26
Role of the His-Cys finger of Moloney murine leukemia virus integrase protein in integration and disintegration. J Virol (1993) 1.25
Folding of the multidomain human immunodeficiency virus type-I integrase. Protein Sci (1994) 1.20
Expression and partial purification of enzymatically active recombinant Ty1 integrase in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1994) 1.14
Mapping viral DNA specificity to the central region of integrase by using functional human immunodeficiency virus type 1/visna virus chimeric proteins. J Virol (1998) 1.09
Reverse Transcriptase and Cellular Factors: Regulators of HIV-1 Reverse Transcription. Viruses (2009) 1.03
Functional domains of Moloney murine leukemia virus integrase defined by mutation and complementation analysis. J Virol (1996) 1.01
Mutations in nonconserved domains of Ty3 integrase affect multiple stages of the Ty3 life cycle. J Virol (1999) 1.00
Integrase residues that determine nucleotide preferences at sites of HIV-1 integration: implications for the mechanism of target DNA binding. Nucleic Acids Res (2014) 0.96
Posttranslational acetylation of the human immunodeficiency virus type 1 integrase carboxyl-terminal domain is dispensable for viral replication. J Virol (2006) 0.93
In vitro activities of purified visna virus integrase. J Virol (1994) 0.93
Reversion of a human immunodeficiency virus type 1 integrase mutant at a second site restores enzyme function and virus infectivity. J Virol (1996) 0.92
Integrase-lexA fusion proteins incorporated into human immunodeficiency virus type 1 that contains a catalytically inactive integrase gene are functional to mediate integration. J Virol (2000) 0.91
Assembly and catalysis of concerted two-end integration events by Moloney murine leukemia virus integrase. J Virol (2001) 0.88
Uneven genetic robustness of HIV-1 integrase. J Virol (2014) 0.88
Efficient gap repair catalyzed in vitro by an intrinsic DNA polymerase activity of human immunodeficiency virus type 1 integrase. J Virol (1998) 0.85
Detection and characterization of a functional complex of human immunodeficiency virus type 1 integrase and its DNA substrate by UV cross-linking. J Virol (1994) 0.85
Retroviral Integrase Structure and DNA Recombination Mechanism. Microbiol Spectr (2015) 0.83
Functional interactions of the HHCC domain of moloney murine leukemia virus integrase revealed by nonoverlapping complementation and zinc-dependent dimerization. J Virol (1999) 0.82
Implication of a central cysteine residue and the HHCC domain of Moloney murine leukemia virus integrase protein in functional multimerization. J Virol (1998) 0.82
Role of host-encoded proteins in restriction of retroviral integration. Front Microbiol (2012) 0.81
Retroviral integrase protein and intasome nucleoprotein complex structures. World J Biol Chem (2017) 0.75
Structural dynamics of native and V260E mutant C-terminal domain of HIV-1 integrase. J Comput Aided Mol Des (2015) 0.75
Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: significance for viral replication. Trends Biochem Sci (1998) 3.78
Deficiency of 60 to 70S RNA in murine leukemia virus particles assembled in cells treated with actinomycin D. J Virol (1974) 3.37
Murine leukemia virus mutant with a frameshift in the reverse transcriptase coding region: implications for pol gene structure. J Virol (1984) 2.32
HIV-1 nucleocapsid protein induces "maturation" of dimeric retroviral RNA in vitro. Proc Natl Acad Sci U S A (1996) 2.30
Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. J Virol (2001) 2.17
Synthesis of murine leukemia virus proteins associated with virions assembled in actinomycin D-treated cells: evidence for persistence of viral messenger RNA. Proc Natl Acad Sci U S A (1976) 2.14
Analysis of arbovirus ribonucleic acid forms by polyacrylamide gel electrophoresis. J Virol (1971) 2.10
Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages. Nucleic Acids Res (1987) 2.06
Selective packaging of host tRNA's by murine leukemia virus particles does not require genomic RNA. J Virol (1979) 2.04
Translational suppression in retroviral gene expression. Adv Virus Res (1992) 1.93
Mutant of B-tropic murine leukemia virus synthesizing an altered polymerase molecule. J Virol (1979) 1.90
Zinc finger structures in the human immunodeficiency virus type 1 nucleocapsid protein facilitate efficient minus- and plus-strand transfer. J Virol (2000) 1.88
Membrane-associated replication complex in arbovirus infection. J Virol (1972) 1.83
Human immunodeficiency virus type 1 nucleocapsid protein reduces reverse transcriptase pausing at a secondary structure near the murine leukemia virus polypurine tract. J Virol (1996) 1.83
Characterization of a DNA binding domain in the C-terminus of HIV-1 integrase by deletion mutagenesis. Nucleic Acids Res (1993) 1.79
Properties of an adenovirus type 2 mutant, Ad2dl807, having a deletion near the right-hand genome terminus: failure to help AAV replication. Virology (1983) 1.69
Effect of polymerase mutations on packaging of primer tRNAPro during murine leukemia virus assembly. J Virol (1981) 1.66
Murine leukemia virus pol gene products: analysis with antisera generated against reverse transcriptase and endonuclease fusion proteins expressed in Escherichia coli. J Virol (1986) 1.55
Specific membranous structures associated with the replication of group A arboviruses. J Virol (1972) 1.54
Sequence and structural determinants required for priming of plus-strand DNA synthesis by the human immunodeficiency virus type 1 polypurine tract. J Virol (1996) 1.53
Use of a sensitive neutralization assay to measure the prevalence of antibodies to the human immunodeficiency virus. J Infect Dis (1988) 1.49
Chromatographic analysis of the aminoacyl-tRNAs which are required for translation of codons at and around the ribosomal frameshift sites of HIV, HTLV-1, and BLV. Virology (1989) 1.47
Identification of amino acids inserted during suppression of UAA and UGA termination codons at the gag-pol junction of Moloney murine leukemia virus. Proc Natl Acad Sci U S A (1990) 1.45
Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates. J Infect Dis (2000) 1.40
Alanine-scanning mutations in the "primer grip" of p66 HIV-1 reverse transcriptase result in selective loss of RNA priming activity. J Biol Chem (1997) 1.36
Suppression of UAA and UGA termination codons in mutant murine leukemia viruses. J Virol (1989) 1.32
Translational readthrough of the murine leukemia virus gag gene amber codon does not require virus-induced alteration of tRNA. J Virol (1989) 1.28
A mechanism for plus-strand transfer enhancement by the HIV-1 nucleocapsid protein during reverse transcription. Biochemistry (2000) 1.23
Molecular requirements for human immunodeficiency virus type 1 plus-strand transfer: analysis in reconstituted and endogenous reverse transcription systems. J Virol (1999) 1.22
Actinomycin D inhibits human immunodeficiency virus type 1 minus-strand transfer in in vitro and endogenous reverse transcriptase assays. J Virol (1998) 1.21
Defects in primer-template binding, processive DNA synthesis, and RNase H activity associated with chimeric reverse transcriptases having the murine leukemia virus polymerase domain joined to Escherichia coli RNase H. Biochemistry (1995) 1.18
Interactions of murine leukemia virus core components: characterization of reverse transcriptase packaged in the absence of 70S genomic RNA. J Virol (1977) 1.17
Metabolism of viral RNA in murine leukemia virus-infected cells; evidence for differential stability of viral message and virion precursor RNA. J Virol (1981) 1.17
Characterization of the herpes simplex virus type 1 glycoprotein D mRNA and expression of this protein in Xenopus oocytes. Nucleic Acids Res (1983) 1.16
Residues in the alphaH and alphaI helices of the HIV-1 reverse transcriptase thumb subdomain required for the specificity of RNase H-catalyzed removal of the polypurine tract primer. J Biol Chem (1999) 1.12
Mutating a conserved motif of the HIV-1 reverse transcriptase palm subdomain alters primer utilization. Biochemistry (1997) 1.12
A large deletion in the connection subdomain of murine leukemia virus reverse transcriptase or replacement of the RNase H domain with Escherichia coli RNase H results in altered polymerase and RNase H activities. Biochemistry (1993) 1.09
Multiple regions of Harvey sarcoma virus RNA can dimerize in vitro. J Virol (1995) 1.07
Codon-specific binding of deacylated transfer ribonucleic acid to ribosomes. J Biol Chem (1970) 1.03
Chromatin-like structure of adeno-associated virus DNA in infected cells. J Virol (1983) 1.03
Host effect on arbovirus replication: appearance of defective interfering particles in murine cells. J Virol (1973) 1.02
Ribonucleic acid codons and protein synthesis. 13. RNA codon recognition by deacylated tRNA and aminoacyl-tRNA. J Mol Biol (1968) 0.99
Macromolecular requirements for abrogation of Fv-1 restriction by murine leukemia viruses. J Virol (1980) 0.95
Hospices for terminally ill patients. The California experience. West J Med (1978) 0.94
Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies. J Biol Stand (1989) 0.92
Functional analysis of reverse transcription by a frameshift pol mutant of murine leukemia virus. Virology (1985) 0.92
Preparation of oocytes for microinjection of RNA and DNA. Methods Enzymol (1987) 0.90
Early response gene expression during differentiation of cultured Leishmania donovani. Parasitol Res (2001) 0.88
Survey results after one year's experience with the Natural Death Act. September 1, 1976--August 31, 1977. West J Med (1978) 0.87
Sensitive hemagglutination inhibition test for mumps antibody. J Clin Microbiol (1981) 0.87
Reactivity of an HIV gag gene polypeptide expressed in E. coli with sera from AIDS patients and monoclonal antibodies to gag. Biochim Biophys Acta (1988) 0.86
Expression of HIV-1 integrase in E. coli: immunological analysis of the recombinant protein. AIDS Res Hum Retroviruses (1990) 0.86
Generation of HIV-1/HIV-2 cross-reactive peptide antisera by small sequence changes in HIV-1 reverse transcriptase and integrase immunizing peptides. J Biomed Sci (1998) 0.83
Morphogenesis of C-type and A-type particles in cells infected by an arbovirus. J Natl Cancer Inst (1973) 0.82
Microinjection into Xenopus oocytes: equipment. Methods Enzymol (1987) 0.80
Readthrough suppression in the mammalian type C retroviruses and what it has taught us. New Biol (1992) 0.79
Epitope mapping of the HIV-1 gag region by analysis of gag gene deletion fragments expressed in Escherichia coli defines eight antigenic determinants. AIDS Res Hum Retroviruses (1990) 0.79
Susceptibility of the Sf9 insect cell line to infection with adventitious viruses. Biologicals (1994) 0.78
Transfer of murine leukaemia and murine sarcoma virus genetic information by transfection with isolated metaphase chromosomes. J Gen Virol (1982) 0.78
Aggressive concern for society as a whole. West J Med (1987) 0.78
Conformation-dependent recognition of baculovirus-expressed Epstein-Barr virus gp350 by a panel of monoclonal antibodies. J Gen Virol (1993) 0.77
St Louis encephalitis virus establishes a productive, cytopathic and persistent infection of Sf9 cells. J Gen Virol (1993) 0.76
Mapping of the epitopes of Epstein-Barr virus gp350 using monoclonal antibodies and recombinant proteins expressed in Escherichia coli defines three antigenic determinants. J Gen Virol (1991) 0.76
Violence by handguns-commentary. West J Med (1981) 0.75
The effect of deacylated tRNA on enzymatic binding of N-formyl-methionyl-tRNA to ribosomes. Biochem Biophys Res Commun (1969) 0.75